Many common antibiotics, from amoxicillin to hospital drugs given by drip, come paired with a second ingredient whose only job is to protect the first. Many bacteria make enzymes that break these antibiotics apart before they can kill the germ. The partner drug acts as a bodyguard, jamming the enzyme rather than attacking the bacteria itself. Bacteria keep evolving ways around each new bodyguard, which is why doctors have moved from older pairings like Augmentin to a growing list of newer combinations.
How the Bacteria’s Defensive Enzyme Works
Penicillins, cephalosporins and carbapenems all share a small four-sided ring that lets them stop bacteria from building their cell walls. That ring is called the beta-lactam ring, which is why these drugs are called beta-lactams. The enzymes bacteria use to break the ring are called beta-lactamases. Most of them use a serine, a building block in the enzyme’s working pocket, to grab the antibiotic, then release it ruined in a second step.1PubMed. Structure, Function of Serine and Metallo-β-lactamases and their Inhibitors2PubMed Central. The Mechanisms of Catalysis by Metallo β-Lactamases Because the enzyme is released unharmed, one molecule can destroy many antibiotic molecules in a row.
Inhibitors exploit the same grab. Most are shaped enough like the antibiotic that the enzyme seizes them instead. Once grabbed, the inhibitor jams the pocket, and the enzyme can no longer chew through the real antibiotic.
On your prescription, this shows up as two drugs in one product. Augmentin is amoxicillin plus clavulanate, and Zosyn is piperacillin plus tazobactam. The first-named drug kills the bacteria and the second protects it. Plain amoxicillin fails against infections from enzyme-making bacteria, which is why the pair exists. People often assume the second ingredient is a second antibiotic. Most inhibitors barely harm bacteria on their own, and their value lies entirely in keeping the partner antibiotic intact. A few newer ones are exceptions that also hit bacteria directly, covered below.
The enzyme is hard to outrun partly because of where it sits. Bacteria often store or release it in the space just outside their inner membrane, so it can destroy the antibiotic before the drug reaches the wall-building proteins it needs to hit. Some bacteria make the enzyme constantly, while others switch it on only when they sense wall damage from an antibiotic, so the same species can look vulnerable in one test and resistant in another.
The Four Enzyme Families and Why They Matter
The most widely used system sorts beta-lactamases into classes A, B, C and D by how similar their protein building blocks are.3Microbe Online. Beta-Lactamase Classification: Ambler vs. Bush-Jacoby, and Why an Enzyme Has Both4Streck. Ambler Classification of β-lactamases Classes A, C and D all work with serine, while class B uses zinc in its working pocket.5PubMed Central. Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance The zinc holds a water molecule that splits the antibiotic directly, without the grab-and-release step that inhibitors exploit.6PubMed. Structure, Function of Serine and Metallo-β-lactamases and their Inhibitors7PubMed Central. The Mechanisms of Catalysis by Metallo β-Lactamases An inhibitor designed to jam a serine pocket has nothing to latch onto.
Some serine classes also shrug off the older inhibitors. Class C enzymes, often called AmpC, are not stopped by clavulanate or tazobactam.8InfectiousDiseaseHub. Why Some Antibiotics Just Don’t Stand a Chance: Understanding β-Lactamases Many class D enzymes, called OXA, are poorly blocked by clavulanate.9InfectiousDiseaseHub. Why Some Antibiotics Just Don’t Stand a Chance: Understanding β-Lactamases Bacteria carrying these can resist Augmentin and Zosyn despite the inhibitor.
On a lab report or in a doctor’s explanation, you may hear these names. TEM and SHV are common class A enzymes. KPC is also class A, but it can destroy last-line antibiotics. NDM and VIM are zinc enzymes, the hardest to treat. OXA names mark class D enzymes.
The class matters because it largely determines which inhibitor combinations have a chance of working, which is why labs try to identify it for serious infections. Class A enzymes like TEM are often controlled by older inhibitors, while KPC needs a newer one such as avibactam.
Classic Inhibitors That Sacrifice Themselves
Clavulanate, tazobactam and sulbactam are often called suicide inhibitors. Clavulanate bonds to the enzyme’s serine, then rearranges into a more reactive form that attacks a second spot in the pocket, and the enzyme is permanently switched off.10Wikipedia. Clavulanic acid Tazobactam breaks into fragments while still stuck to the serine, leaving the enzyme dead.11PubMed. Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 –>Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition Either way, each inhibitor molecule can knock out only one enzyme molecule.
That one-for-one trade is the weakness. A bacterium that makes enough enzyme can simply outnumber the inhibitor. These older inhibitors also mainly cover class A enzymes, not AmpC or zinc enzymes.12InfectiousDiseaseHub. Why Some Antibiotics Just Don’t Stand a Chance: Understanding β-Lactamases
You meet each of them in different settings. Clavulanate comes with amoxicillin, mostly as tablets for ear, sinus and bite infections. Tazobactam comes with piperacillin, given by drip in hospital. Sulbactam pairs with ampicillin, also as a hospital drip, and it kills Acinetobacter bacteria directly, a point that returns later.
They are not interchangeable. The three differ in how strongly they block various class A enzymes, so one cannot simply be swapped for another. Tazobactam is generally the stronger against a wider set of class A enzymes, which is part of why it is paired with a broad hospital antibiotic.
Enough inhibitor must reach the infection to match the enzyme load, and missed doses let enzyme levels rebound. Kidneys clear both the antibiotic and the inhibitor, so doctors adjust both together in kidney failure.
“Permanently disabled” applies only to the enzyme molecule that was hit. The bacterium can keep making fresh enzyme from its genes, so protection lasts only while enough inhibitor keeps arriving. That is why the inhibitor must be present along with the antibiotic at the same time, not given separately hours apart.
Newer Inhibitors That Reuse Themselves or Do Double Duty
Avibactam has no beta-lactam ring yet still bonds to the enzyme’s serine.13PubMed Central. Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor Instead of breaking, it later snaps back into its original shape and comes off intact.14PubMed Central. Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor15PubMed Central. Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study The same molecule can then block the same or another enzyme, so it avoids the one-for-one trade that limits clavulanate. It also blocks KPC, a class A enzyme that destroys carbapenems.16PubMed Central. Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study
Vaborbactam is an approved inhibitor built around boron.17PubMed. Boronic Acid Inhibitors of β-Lactamases: A Promising Strategy Against Antimicrobial Resistance Boron lets it mimic the short-lived shape the antibiotic takes while being cut, so the enzyme holds it tightly but reversibly.18PubMed. Boronic Acid Inhibitors of β-Lactamases: A Promising Strategy Against Antimicrobial Resistance Taniborbactam and xeruborbactam are boron drugs still being tested.19PubMed. Boronic Acid Inhibitors of β-Lactamases: A Promising Strategy Against Antimicrobial Resistance
Some new inhibitors also attack bacteria. Zidebactam blocks serine enzymes and also binds one of the bacteria’s wall-building proteins.20PubMed. Zidebactam as a new approved β-Lactamase inhibitor with intrinsic antibacterial activity via PBP2 binding That boosts its partner antibiotic even when it can’t kill bacteria alone.21PubMed Central. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates Durlobactam paired with sulbactam lowered the dose needed against Acinetobacter about 32-fold in lab testing.22PubMed Central. Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii
In hospital, the names look like this: ceftazidime-avibactam pairs a cephalosporin with avibactam, and meropenem-vaborbactam pairs a carbapenem with a boron inhibitor. Cefepime-zidebactam and sulbactam-durlobactam are among the newest. Names ending in -bactam usually signal the inhibitor.
These combinations are usually saved for serious infections, to slow resistance. They are given by drip, not as pills, and doctors try to confirm the enzyme type or susceptibility, though treatment may start before results return.
Why Zinc Enzymes Remain the Hardest Problem
Zinc enzymes don’t use serine, so serine-targeting inhibitors like avibactam leave them working. Researchers therefore design compounds that bind the zinc itself or lock onto it with the nearby protein.23PubMed Central. Current Strategy for Targeting Metallo-β-Lactamase with Metal-Ion-Binding Inhibitors Some experimental compounds work partly by pulling the zinc out of NDM-1 and VIM-2 enzymes.24PubMed. Optimization of 1,2,4-Triazole-3-thiones toward Broad-Spectrum Metallo-β-lactamase Inhibitors Showing Potent Synergistic Activity on VIM- and NDM-1-Producing Clinical Isolates These remain in early development.
For a patient with an NDM or VIM infection, standard combinations may fail. Doctors may use cefiderocol or combine aztreonam with avibactam. Treatment often needs an infectious disease specialist, and lab testing guides the exact choice.
The stakes are high because of what these enzymes destroy. Carbapenems are a family of powerful antibiotics, and drugs such as meropenem are often the last line of defense. Enzymes such as KPC and NDM break them down, and older fallbacks like colistin are harder on the kidneys.
How Bacteria Become Resistant to Inhibitors
Bacteria can change the enzyme. A single change at one spot in common class A enzymes can make them resist clavulanate and tazobactam.25PubMed. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130 One SHV variant needed 9 times more clavulanate to be blocked, yet tazobactam still worked.26PubMed Central. Characterization of the inhibitor-resistant SHV β-lactamase SHV-107 in a clinical Klebsiella pneumoniae strain coproducing GES-7 enzyme So resistance to one inhibitor does not always mean resistance to all. Changes in a flexible loop of KPC weaken avibactam and let ceftazidime-avibactam fail, but those same changes can make the bacteria sensitive to meropenem again.27PubMed Central. Resistance development in KPC-producing Klebsiella pneumoniae under ceftazidime/avibactam-meropenem pressure: KPC-2 Ω-loop mutations attenuate avibactam efficacy
That last pattern is a trade-off. A change that lets an enzyme escape an inhibitor often makes it worse at breaking down the antibiotic itself. Some bacteria therefore resist an inhibitor but become vulnerable to the partner antibiotic alone, giving doctors another option.
Bacteria can also outnumber the inhibitor. Exposed to piperacillin-tazobactam, one E. coli strain multiplied its enzyme gene up to 113 copies per cell, making enough enzyme to use up all the tazobactam.28PubMed Central. Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli Klebsiella can do the same, letting a few cells survive doses that seem effective.29PubMed Central. Heteroresistance to piperacillin/tazobactam in Klebsiella pneumoniae is mediated by increased copy number of multiple β-lactamase genes
A third route is keeping the drug out. Pseudomonas pumps can push some inhibitors back out of the cell.30PubMed Central. Beta-lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa Losing entry channels in the outer wall can reduce how much vaborbactam gets in.31PubMed Central. Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria
When treatment stops working, an infection often improves and then returns during or after treatment. A repeat culture may show new resistance, and doctors switch based on the new lab result. Hospitals may isolate patients to stop spread. Because enzyme changes affect each inhibitor differently, labs usually test the exact combination being considered rather than guessing from a related one.
How Doctors Pick the Right Combination
Rapid gene tests can identify carbapenem-destroying enzymes and change early treatment choices.32PubMed. Interpreting the results of rapid molecular diagnostic tests for carbapenem-resistant Enterobacterales infection: current clinical perspective while waiting for further evidence Knowing a KPC from an NDM tells doctors whether avibactam-type drugs can work. An experimental color-change test identified enzyme types in 15 minutes to 3 hours, and it raised correct antibiotic choices from about half of cases to most cases in that test.33PubMed Central. Rapid and visual identification of β-lactamase subtypes for precision antibiotic therapy What a resistance gene predicts, though, depends on which genes are common locally.34PubMed Central. 608Can Rapid Molecular Diagnostics Assist in the Choice of b-Lactam Antibiotics? An Analysis of Data from PRIMERS-II of the Antibiotic Resistance Leadership Group (ARLG)
A gene test shows whether a resistance gene is present, not always whether the bacterium is making enough enzyme to resist. Standard culture and susceptibility testing is therefore still used to confirm the best drug, often arriving a day or two later. Doctors use the fast result to choose a reasonable early treatment and adjust when the full result comes back.
Newer combinations are showing results. Sulbactam-durlobactam worked as well as colistin against serious Acinetobacter infections and was well tolerated.35PubMed. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) More than 96% of resistant Acinetobacter samples were susceptible to it in lab testing.36PubMed Central. Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii
If a relative has a resistant infection, useful questions include what organism and enzyme were found, whether a newer combination is an option, whether kidney function changes the dose, and how long results take.
Where These Bacterial Enzymes Came From
Beta-lactamases date back millions of years and nearly 2,800 distinct versions are known.37PubMed Central. Past and Present Perspectives on β-Lactamases They likely arose in soil bacteria defending against natural antibiotics made by other microbes.38PubMed Central. Past and Present Perspectives on β-Lactamases Many soil microbes produce such antibiotics to compete with neighbors, and nearby bacteria evolved enzymes to survive them. The enzyme was a defense in an ancient chemical rivalry long before any human medicine existed.
Some of these genes moved from environmental bacteria into disease-causing ones, a shift sped up by 70 years of medical use.39Evolutionary Biology of Bacterial and Fungal Pathogens. Epidemiology and Evolution of Beta-Lactamases Bacteria can pass genes on small movable pieces of DNA to other bacteria, even of different species, and heavy antibiotic use in hospitals and farming gives carriers a survival edge. The clinical and environmental versions of SHV share one large gene pool,40PubMed Central. The Evolutionary Histories of Clinical and Environmental SHV β-lactamases are Intertwined so new resistance can keep arriving from the environment.